Atara Biotherapeutics
ATRA
48 hedge funds and large institutions have $24.1M invested in Atara Biotherapeutics in 2024 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 11 increasing their positions, 21 reducing their positions, and 47 closing their positions.
296% more call options, than puts
Call options by funds: $265K | Put options by funds: $67K
54.61% more ownership
Funds ownership: 3.27% → 57.88% (+55%)
41% less funds holding
Funds holding: 82 → 48 (-34)
48% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 21
58% less capital invested
Capital invested by funds: $57.9M → $24.1M (-$33.8M)
72% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 47
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Centiva Capital
New York
|
+$2.11M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$1.54M |
| 3 |
Millennium Management
New York
|
+$1.54M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$1.23M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$546K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.44M |
| 2 |
BlackRock
New York
|
-$3.19M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1.35M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.28M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.16M |
ATRA Hedge Fund Activity: Q2 2024 in Review
48 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q2 2024, worth a combined $24.1M — down 58% from $57.9M a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of ATRA and 13 opened new positions — a net loss of 34 holders — while 21 trimmed existing stakes and 11 added.
The largest buyer was Centiva Capital, opening a new position worth an estimated $2.11M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $3.44M sold.
- 48 institutional investors held Atara Biotherapeutics (ATRA) as of Q2 2024, down from 82 in Q1 2024.
- Funds reported $24.1M of Atara Biotherapeutics stock for Q2 2024, down 58% quarter-over-quarter.
- 13 funds opened new Atara Biotherapeutics positions in Q2 2024 and 47 closed out, a net change of -34 holders.
- The largest Atara Biotherapeutics buyer in Q2 2024 was Centiva Capital, an estimated $2.11M added.
- The largest Atara Biotherapeutics seller in Q2 2024 was T. Rowe Price Associates, an estimated $3.44M sold.
Based on aggregated 13F filings for Q2 2024.